KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Amortization of Deferred Charges: 2017-2025

Historic Amortization of Deferred Charges for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $5.0 million.

  • Amneal Pharmaceuticals' Amortization of Deferred Charges fell 37.34% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year decrease of 5.24%. This contributed to the annual value of $29.1 million for FY2024, which is 151.97% up from last year.
  • Amneal Pharmaceuticals' Amortization of Deferred Charges amounted to $5.0 million in Q3 2025, which was down 26.84% from $6.9 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Amortization of Deferred Charges registered a high of $8.0 million during Q3 2024, and its lowest value of $2.1 million during Q1 2023.
  • Over the past 3 years, Amneal Pharmaceuticals' median Amortization of Deferred Charges value was $6.8 million (recorded in 2024), while the average stood at $5.4 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Amortization of Deferred Charges skyrocketed by 240.03% in 2024 and then plummeted by 37.34% in 2025.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Amortization of Deferred Charges stood at $2.3 million in 2021, then fell by 9.61% to $2.1 million in 2022, then soared by 121.46% to $4.7 million in 2023, then skyrocketed by 46.16% to $6.8 million in 2024, then crashed by 37.34% to $5.0 million in 2025.
  • Its Amortization of Deferred Charges was $5.0 million in Q3 2025, compared to $6.9 million in Q2 2025 and $6.8 million in Q1 2025.